Ms. Jenna McNeil reports

APPILI THERAPEUTICS ANNOUNCES RESULTS OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

Appili Therapeutics Inc. has released the results from its annual and special meeting of shareholders held earlier today.

Based on the proxies received and the vote conducted at the meeting, all tabled resolutions were approved by the shareholders of the company, including the election of the following directors for the ensuing year: Don Cilla, Brian Bloom, Theresa Matkovits, Juergen Froehlich, Armand Balboni and Prakash Gowd.

Voting results for each director are summarized in the attached table.

All other matters considered at the meeting were approved by shareholders, including the reappointment of PricewaterhouseCoopers LLP, chartered accountants, as the independent auditor of the company for the ensuing year and authorizing the directors of the company to fix its remuneration, a special resolution approving the company's continuation from a corporation governed under the Canada Business Corporations Act to a corporation governed under the Business Corporations Act (Ontario) (OBCA), and a special resolution to authorize the board of directors of the company, following the continuance, to set the number of directors from time to time within the minimum and maximum number of directors set forth in the articles of the company, in accordance with Section 125(3) of the OBCA.

The company has filed a report of the voting results on all resolutions voted on the meeting on the company's SEDAR+ profile.

About Appili Therapeutics Inc.

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio driven and people focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili's goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The company is currently advancing a diverse range of anti-infectives, including a U.S. Food and Drug Administration-approved ready-made suspension of metronidazole for the treatment of anti-microbial infections, a vaccine candidate to eliminate a serious biological weapon threat and a topical anti-parasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicentre of the global fight against infection.